Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBT-1 + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- CBA Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CBT-1 + paclitaxel + carboplatin is a combination regimen under investigation for cancer therapy. CBT-1 is an orally administered small molecule inhibitor of P-glycoprotein (P-gp, also known as multidrug resistance protein 1, MDR1, or ABCB1), a membrane transporter responsible for multidrug resistance in cancer cells. CBT-1 is designed to block P-gp-mediated drug efflux, potentially enhancing the efficacy of chemotherapies that are P-gp substrates. Paclitaxel is a microtubule-stabilizing agent that disrupts cell division, and carboplatin is a DNA cross-linking platinum compound. This combination aims to improve responses in tumors known for developing resistance, particularly through the action of CBT-1 reversing multidrug resistance and enhancing the cytotoxicity of paclitaxel and carboplatin. Preclinical and early clinical data show that CBT-1 can potentiate the effects of taxanes and platinum agents in resistant cancer models.
- Other names
- bisbenzylisoquinoline P-glycoprotein inhibitor + paclitaxel + carboplatin
02
Targets
DNAABCB1 (P-glycoprotein)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CBT-1 + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBT-1 + paclitaxel + carboplatin.